NEW YORK, Dec. 16, 2022 /PRNewswire/ -- Shareholder rights law firm Julie & Holleman is investigating the proposed acquisition of Myovant Sciences (NYSE:MYOV) by affiliates of its controlling shareholder, Sumitovant Biopharma, an affiliate of Japanese conglomerate Sumitomo. Under the terms of the deal, Sumitovant will acquire all the outstanding shares of Myovant common stock it does not already own for $27 per share in cash, or a total of approximately $1.7 billion.
Read more at prnewswire.comMYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
/Quantum%20Computing/A%20concept%20image%20showing%20a%20ray%20of%20light%20passing%20through%20cyberspace_%20Image%20by%20metamorworks%20via%20Shutterstock_.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)